Françoise Meunier will become Director of Special Projects for the European Organization for Research and Treatment of Cancer starting April 1, 2015.
After 24 years of working as Director General of the European Organization for Research and Treatment of Cancer (EORTC), Françoise Meunier will move to a new role within the Brussels-based operation. She will become Director of Special Projects from April 1, 2015.
EORTC has announced that a plenary session in honor of Meunier’s achievements will take place at the Crowne Plaza Brussels-Le Palace in Belgium on March 12, 2015 at 4:00pm local time. The event is designed to recognize her major commitment to the management of pan-European cancer research.
As Director General, Meunier has been involved in the coordination and administration of all activities in order to promote EORTC as a major European research organization. She has been responsible for the organization of scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as for internal and external the communication.
Before joining EORTC in 1991, Meunier was Head of the Infectious Diseases Department at Institute Jules Bordet in Brussels, Belgium, and her personal area of research included the management of infections in patients with Cancer and mainly Invasive Fungal Infections. She was awarded the Belgian Laureate “Prix Femmes d’Europe 2004-2005”, and in 2007 she was conferred the title of Baroness by King Albert II of Belgium. Two years later she received the Pezcoller Foundation award for her contribution to oncology, and she became a fellow of the European Academy of Cancer Sciences in 2011 and a member of the IMI (Innovative Medicine Initiative) Scientific Committee of the European Union in 2012. In 2014, she was appointed council member of the FEAM (Federation of European Academy of Medicine).
The EORTC is an independent research organization dedicated to investigator driven clinical trials and translational research. Consisting of both a network and a coordinating scientific and operational infrastructure, it seeks to not only establish ‘state-of-the-art’ treatments but also ensure that new cancer agents are developed and tested efficiently with the aim of minimizing delays between laboratory discovery and their therapeutic benefit for patients.
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.